Han BY - Search Results

1

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.

Han BY, Chen C, Luo H, Lin CJ, Han XC, Nasir J, Shi JX, Huang W, Shao ZM, Ling H, Hu X. Han BY, et al. Cancer Lett. 2024 Apr 28;588:216763. doi: 10.1016/j.canlet.2024.216763. Epub 2024 Feb 24. Cancer Lett. 2024. PMID: 38403109 Free article.

2

Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China.

Han BY, Li XG, Zhao HY, Hu X, Ling H. Han BY, et al. BMC Cancer. 2020 Mar 23;20(1):244. doi: 10.1186/s12885-020-06724-5. BMC Cancer. 2020. PMID: 32293328 Free PMC article.

3

Clinicopathological Characteristics and Survival Outcomes of Mammary Paget's Disease: A Retrospective Study Based on a Chinese Population.

Han BY, Xu XL, Zhu XZ, Han XC, Hu X, Ling H. Han BY, et al. Among authors: han xc. Cancer Manag Res. 2022 Jan 18;14:237-247. doi: 10.2147/CMAR.S338788. eCollection 2022. Cancer Manag Res. 2022. PMID: 35125891 Free PMC article.

4

Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China.

Han B, Gu Z, Liu Z, Ling H. Han B, et al. Cancer Manag Res. 2022 Feb 16;14:647-658. doi: 10.2147/CMAR.S346319. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210861 Free PMC article.

5

HNRNPU promotes the progression of triple-negative breast cancer via RNA transcription and alternative splicing mechanisms.

Han BY, Liu Z, Hu X, Ling H. Han BY, et al. Cell Death Dis. 2022 Nov 8;13(11):940. doi: 10.1038/s41419-022-05376-6. Cell Death Dis. 2022. PMID: 36347834 Free PMC article.

6

Integrated Multi-Omics Profiling of Young Breast Cancer Patients Reveals a Correlation between Galactose Metabolism Pathway and Poor Disease-Free Survival.

Han X, Han B, Luo H, Ling H, Hu X. Han X, et al. Cancers (Basel). 2023 Sep 19;15(18):4637. doi: 10.3390/cancers15184637. Cancers (Basel). 2023. PMID: 37760606 Free PMC article.

7

Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer.

Yang W, Hong L, Guo L, Wang Y, Han X, Han B, Xing Z, Zhang G, Zhou H, Chen C, Ling H, Shao Z, Hu X. Yang W, et al. Cell Discov. 2024 Sep 17;10(1):96. doi: 10.1038/s41421-024-00715-7. Cell Discov. 2024. PMID: 39285160 Free PMC article.

8

Multiomics and single-cell sequencings reveal the specific biological characteristics of low Ki-67 triple-negative breast cancer.

Han B, Han X, Luo H, Nasir J, Chen C, Shao Z, Ling H, Hu X. Han B, et al. Cancer Innov. 2024 Sep 19;3(5):e146. doi: 10.1002/cai2.146. eCollection 2024 Oct. Cancer Innov. 2024. PMID: 39301202 Free PMC article.

9

High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer.

Chen L, Zhu X, Han B, Ji L, Yao L, Wang Z. Chen L, et al. Front Oncol. 2021 Apr 13;11:630432. doi: 10.3389/fonc.2021.630432. eCollection 2021. Front Oncol. 2021. PMID: 33928027 Free PMC article.

10

Conductive single enzyme nanocomposites prepared by in-situ growth of nanoscale polyaniline for high performance enzymatic bioelectrode.

Kim HS, Ahn K, Han BY, Haque AJ, Kim S, Kim S, Wee Y, Kim J. Kim HS, et al. Among authors: han by. Biosens Bioelectron. 2025 Jan 1;267:116841. doi: 10.1016/j.bios.2024.116841. Epub 2024 Oct 15. Biosens Bioelectron. 2025. PMID: 39406565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters